This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Investors Shun Bed Bath & Beyond, Walgreens Growth Deals

NEW YORK ( TheStreet) -- After growing earnings from post-recession lows, companies like Bed Bath & Beyond (BBBY - Get Report) and Walgreens (WAG) have recently cut their biggest ever acquisitions in an effort to retool earnings prospects and growth.

The problem is that in a lukewarm earnings environment, investors have punished both companies - in part - for the moves. Now, it's time for investors to question whether widespread corporate austerity can be a long-term opportunity for the companies that are mapping out new growth plans.

In May, Bed Bath & Beyond (BBBY - Get Report) cut its biggest-ever acquisition when it bought Cost Plus World Market (CPWM) for nearly $500 million, in a deal that was seen as a way to combat a slowdown at the brick-and-mortar home goods store. Initially, the move pushed Bed Bath & Beyond to all-time highs over $75 a share as many perceived the deal to be a smart growth play.

After announcing a second quarter sales and profit margin slowdown on Wednesday and providing a cloudy outlook for the remainder of 2012, investors are punishing Bed Bath & Beyond shares, pushing them nearly 15% lower to $62.96 in Thursday trading, erasing share gains since the Cost Plus deal. But faced with less-than-stellar comparable store sales and earnings, the strategic benefits of the acquisition may be all the more clear.

Many analysts reacted to the Union, N.J.-based retailers share slump as overdone, citing high expectations for Bed Bath & Beyond's M&A and continued strong execution by management. Credit Suisse analyst Gary Balter, who raised his Bed Bath & Beyond price target to $91 after the Cost Plus acquisition, said there was "little to like" in the company's earnings and guidance. When pressed to decide whether the earnings show growth has peaked at Bed Bath & Beyond or if the company's M&A will revive sales, Balter remains a bull.

"We believe investors are overreacting to the costs of the acquisitions and underestimating the benefits," wrote Balter in a note reacting to earnings. "We are especially excited by the Cost Plus acquisition, which we believe can provide significant sourcing and comp opportunities in the future," he added, noting that part of Bed Bath & Beyond's guidance miss comes from costs associated with the acquisition that should have been expected.

After successfully competing with the likes of Web-based competitor Amazon (AMZN)and big box retailers, acquiring new channels of growth may not be such a bad bet for Bed Bath & Beyond, after posting a 30%-plus three year growth rate of earnings.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
WAG $81.65 2.05%
BBBY $47.22 0.00%
CVS $100.50 0.00%
ESRX $73.73 0.00%
AAPL $93.74 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs